PodParley PodParley
PodParley
Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more episode artwork

EPISODE · Jun 4, 2024 · 13 MIN

Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more

from JAMA Editors' Summary

Editor's Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 4, 2024, issue.

Episode metadata supplied by the publisher feed · Published Jun 4, 2024

Embed this episode

NOW PLAYING

Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more

0:00 13:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JAMA Editors' Summary?

This episode is 13 minutes long.

When was this JAMA Editors' Summary episode published?

This episode was published on June 4, 2024.

Can I download this JAMA Editors' Summary episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!